Vaccine Info

Ad26.ZIKV.001 Zika Vaccine

Authored by
Last reviewed
January 3, 2024

Ad26.ZIKV.001 Zika Vaccine

Ad26.ZIKV.001 Zika Vaccine candidate is a replication-incompetent human adenovirus serotype 26 (ad26) vector. Ad26.ZIKV.001 is an adenovirus serotype 26 vector encoding ZIKV M-Env, administered in 1- or 2-dose regimens of 5 × 1010 or 1 × 1011 viral particles (vp) or placebo. A study published in August 2022 reported that the viral vector vaccine (Ad26.ZIKV.001), seroconversion rate (100%), and GMT peaked after two shots with both low- and high-dose vaccines. 

Janssen Vaccines & Prevention B.V. is the vaccine candidate study sponsor.

Ad26.ZIKV.001 Vaccine Indication

Ad26.ZIKV.001 Zika Vaccine candidate is indicated to induce neutralizing antibodies to prevent Zika virus (ZIKV) infection. ZIKV, a mosquito-borne flavivirus responsible for congenital Zika syndrome (CZS), was first isolated from rhesus monkeys in the Zika forest in Uganda in 1947.ZIKV is transmitted via Aedes aegypti mosquitoes and may cause severe congenital disease after maternal-fetal transmission.

Ad26.ZIKV.001 Vaccine Dosage

In this phase 1 clinical trial, researchers found t doses of Ad26.ZIKV.001 was safe, causing mild to moderate reactogenicity and inducing persistent neutralizing antibody responses. The single dose had lower peak antibodies but was durable after one year. 

Ad26.ZIKV.001 Vaccine News

October 28, 2022 - Current Advances in Zika Vaccine Development.

April 13. 2021 - Phase I Trial Of An Adenovirus Vector Vaccine for Zika Virus Shows High Immunogenicity And Safety

February 16, 2021 - A phase 1 trial of the Ad26.ZIKV.001 Zika vaccine candidate revealed no safety concerns. The antibodies peaked 14 days after the second vaccine and remained high for at least one year.

February 16, 2021 - Estimating the Effect of Discontinuing Universal Screening of Donated Blood for Zika Virus in the 50 U.S. States.

August 24, 2018 - RESEARCH ARTICLE: Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against the ZIKV challenge. In NHP, a single immunization with a typical human dose of 1x1011 vp of Ad26.ZIKV.M-Env also induced Env-binding and ZIKV neutralizing antibodies and Env and M specific cellular immune responses associated with complete protection against viremia from ZIKV challenge as measured in plasma and other body fluids. Together, these data provide the rationale to progress the Ad26.ZIKV.M-Env candidate vaccine to clinical testing.

Ad26.ZIKV.001 Clinical Trials

Clinical Trial NCT03356561: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.ZIKV.001 in 100 Healthy Adult Volunteers - Last Update Posted on October 15, 2019.

On May 16, 2021, the Annals of Internal Medicine reported on the clinical trial. All regimens were well tolerated, with no safety concerns identified. In both 2-dose regimens, ZIKV neutralizing titers peaked 14 days after the second vaccination. However, this study was limited since it was conducted in a nonendemic area, so it did not assess safety and immunogenicity in a flavivirus-exposed population. Conclusion: If the need for a ZIKA vaccine reemerges, Ad26.ZIKV.001 is a promising candidate based on its safety and immunogenicity profile.

Clinical Trials

No clinical trials found